CoChat

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

Open access
Wang, Zijun, Lorenzi, Julio C. C., Muecksch, Frauke, Finkin, Shlomo, Viant, Charlotte, Gaebler, Christian, Cipolla, Melissa, Hoffman, Hans-Heinrich, Oliveira, Thiago Y., Oren, Deena A., Ramos, Victor, Nogueira, Lilian, Michailidis, Eleftherios, Robbiani, Davide F., Gazumyan, Anna, Rice, Charles M., Hatziioannou, Theodora, Bieniasz, Paul D., Caskey, Marina, Nussenzweig, Michel C. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 35

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2020.09.09.288555

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 36

  1. 10.1038/s41586-020-2012-7 · DOI · Paper page
  2. 10.1016/j.cell.2020.02.052 · DOI · Paper page
  3. 10.1016/S0140-6736(20)302518 · doi:10.1016/s0140-6736(20)302518
  4. 10.1126/science.abb2507 · DOI · Paper page
  5. 2020, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor, Nature, 581, 215, 10.1038/s41586-020-2180-5 · DOI · Paper page
  6. A. O. Hassan et al., A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell, (2020). · DOI · Paper page
  7. 10.1146/annurev.iy.04.040186.002133 · doi:10.1146/annurev.iy.04.040186.002133 · Paper page
  8. 10.1146/annurev.iy.03.040185.002233 · DOI · Paper page
  9. 10.1038/nri3322 · DOI · Paper page
  10. F. Wu et al., Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med, (2020). · DOI · Paper page
  11. P. J. M. Brouwer et al., Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science, (2020). · DOI
  12. L. Liu et al., Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature, (2020). · DOI · Paper page
  13. 10.1126/science.abc2241 · DOI · Paper page
  14. T. F. Rogers et al., Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, (2020). · DOI · Paper page
  15. A. Baum et al., REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. bioRxiv, 2020.2008.2002.233320 (2020). · DOI
  16. 10.1038/s41423-020-0474-z · DOI · Paper page
  17. D. Sterlin et al., IgA dominates the early neutralizing antibody response to SARS-CoV-2. medRxiv, 2020.2006.2010.20126532 (2020). · DOI
  18. J. Seow et al., Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).
  19. X. Chi et al., A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, (2020). · DOI · Paper page
  20. 2020, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells, Cell, 182, 73, 10.1016/j.cell.2020.05.025 · DOI · Paper page
  21. F. Schmidt et al., Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 217, (2020). · DOI · Paper page
  22. R. Shi et al., A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, (2020). · DOI · Paper page
  23. 10.1038/nature07930 · DOI · Paper page
  24. Q. Wang et al., A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host Microbe, (2020). · DOI · Paper page
  25. 10.1126/science.abb7269 · DOI · Paper page
  26. 10.1128/CVI.00131-10 · DOI · Paper page
  27. 10.1038/s41577-019-0261-1 · DOI · Paper page
  28. 2020, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell, 181, 1489, 10.1016/j.cell.2020.05.015 · DOI · Paper page
  29. 2020, A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat Med, 26, 1033, 10.1038/s41591-020-0913-5 · DOI · Paper page
  30. 10.1016/j.jim.2007.09.017 · DOI · Paper page
  31. 10.1038/nprot.2016.102 · DOI · Paper page
  32. 10.1016/j.cell.2017.04.024 · DOI · Paper page
  33. 10.1093/nar/gkt382 · DOI · Paper page
  34. 10.1093/bioinformatics/btv359 · DOI · Paper page
  35. 10.1038/s41586-019-0934-8 · DOI · Paper page
  36. 2019, cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence, Front Immunol, 10, 2365, 10.3389/fimmu.2019.02365 · DOI · Paper page

Cited by

Metadata

Authors
Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffman, H.-H., Oliveira, T. Y., Oren, D. A., Ramos, V., Nogueira, L., Michailidis, E., Robbiani, D. F., Gazumyan, A., Rice, C. M., Hatziioannou, T., Bieniasz, P. D., Caskey, M., & Nussenzweig, M. C.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2020-09-09
OpenAlex
W3083815322
Cited by
35
References
7
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.